💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Albert David Limited is an India-based pharmaceutical company. The Company's principal business is manufacturing and trading of pharmaceutical formulations, infusion solutions, herbal dosage forms and bulk drugs by way of domestic sale or export. Its product categories…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A middling business, fully valued — but flagged on governance.
Albert David is scored on the pharma / healthcare framework. It keeps a thin -0.4% of every rupee of sales as net profit. Free cash flow is worth about -2.7% of its market value.
Book value has grown 8%/yr. Return on equity is a weak -0.4%.
At 20× earnings, the stock sits at the 63rd percentile of its own 3-year range — the middle of where it has historically traded. Today's price implies ~9%/yr earnings growth for a decade. The forensic screen raises 2 red flags: Only ₹0.16 of cash per ₹1 profit over 4 years — earnings not converting to cash; 1433% of pre-tax profit is other income, not operations.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 20.11 | — | — |
| P/B | 1.16 | 4.11 | better |
| EV/EBITDA | 10.92 | 19.15 | better |
| ROE | -0.38 | 0.68 | worse |
| ROCE | 0.75 | — | — |
| ROA | 4.35 | 1.26 | better |
| Quick Ratio | 2.74 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue declined 9% in the latest year — a break from prior trajectory. Negative CAGR — the top line has shrunk over this window.
1 of the 4 years shown had a loss — profitability is inconsistent. The latest year saw a -109% swing — check if it's a one-off or structural.
Operating margin has compressed from 14% to 0% — costs or competition are eating into profitability. Interest or tax burden is shrinking — more of the operating profit is reaching the bottom line.
Negative ROE — the business is destroying shareholder value. Capital efficiency declining — ROE down 12pp.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. -31% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
2 of 4 years had negative operating cash flow — profitability on paper may not translate to cash.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 112% sequentially — momentum is building. Wide quarterly swings (53% spread) — likely seasonality, lumpy orders, or project-based revenue.
2 of 4 quarters loss-making — quarterly profitability is uneven. Profit jumped 249% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (-4% → 25%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3y median.
Promoter holding at 62.2% — majority control intact.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.